Skip to main content

Advertisement

SpringerLink
Log in

Clinical management and outcome of 36 invasive prolactinomas treated with dopamine agonist

  • Clinical Study – Patient Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Treatment of invasive prolactinoma, which has several characteristics including invasive growth into cavernous sinuses and formation of giant adenomas compressing adjacent neural structures, resulting in neurological dysfunction, has been very challenging. There are relatively few reports available describing long-term treatment outcome. Herein, we document the results of bromocriptine administration as initial treatment during average 44 months follow-up (up to 12 years) period. We retrospectively categorized 36 patients into four groups according to the results of 3 months of bromocriptine treatment: group 1, tumor volume reduction (TVR) >25% with normalized serum prolactin (NP) (n = 24); group 2, TVR >25% without NP (n = 4); group 3, TVR <25% with NP (n = 5); and group 4, TVR <25% without NP (n = 3). During follow-up, 22 patients (91.7%) in group 1 achieved TVR >50% with NP. Three patients (75%) in group 2 achieved TVR >50% with NP after treatment for 8 months. In group 3, four patients (80.0%) continued medication because of improvement of symptoms and achieved additional TVR (18.8–46.4%). Surgery was performed on five patients (one in group 2, one in group 3, and all three in group 4), and complete resection was achieved in four (80.0%). Overall, 25 (69.4%) of the 36 patients treated with bromocriptine had complete response and 6 (16.7%) had partial response but did not require surgery. Thus, the overall response rate was 86%, with only five patients (14%) requiring surgical debulking. NP was not achieved by surgery alone in all cases, even after total resection of tumor. Patients who achieve TVR >25% with NP with 3 months of bromocriptine administration had a high possibility of showing good long-term response (TVR >50% with NP) to bromocriptine. A higher dose of dopamine agonist (DA) or other DA should be considered for patients who achieve TVR >25% without NP.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Abbreviations

DAs:

Dopamine agonists

MRI:

Magnetic resonance imaging

NP:

Normalized serum prolactin

PRLs:

Prolactin levels

TVR:

Tumor volume reduction

References

  1. Franks S, Jacobs HS, Nabarro JD (1975) Proceedings: studies of prolactin secretion in pituitary disease. J Endocrinol 67:55P

    PubMed  CAS  Google Scholar 

  2. Jeon WY, Kim OL, Kim SH, Bae JH, Choi BY, Cho SH (2001) The surgical result of pituitary adenoma by transsphenoidal approach. J Korean Neurosurg Soc 30:1278–1283

    Google Scholar 

  3. Hubbard JL, Scheithauer BW, Abboud CF, Laws ER (1987) Prolactin-secreting adenomas: the preoperative response to bromocriptine treatment and surgical outcome. J Neurosurg 67:816–821

    Article  PubMed  CAS  Google Scholar 

  4. Barrow DL, Mizuno J, Tindall GT (1988) Management of prolactinomas associated with very high serum prolactin levels. J Neurosurg 68:554–558

    Article  PubMed  CAS  Google Scholar 

  5. Molitch ME (2002) Medical management of prolactin-secreting pituitary adenomas. Pituitary 5:55–65

    Article  PubMed  CAS  Google Scholar 

  6. Molitch ME, Elton RL, Blackwell RE, Caldwell B, Chang RJ, Jaffe R, Joplin G, Robbins RJ, Tyson J, Thorner MO (1985) Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab 60:698–705

    Article  PubMed  CAS  Google Scholar 

  7. Pinzone JJ, Katznelson L, Danila DC, Pauler DK, Miller CS, Klibanski A (2000) Primary medical therapy of micro- and macroprolactinomas in men. J Clin Endocrinol Metab 85:3053–3057

    Article  PubMed  CAS  Google Scholar 

  8. Pollock BE, Cochran J, Natt N, Brown PD, Erickson D, Link MJ, Garces YI, Foote RL, Stafford SL, Schomberg PJ (2008) Gamma knife radiosurgery for patients with nonfunctioning pituitary adenomas: results from a 15-year experience. Int J Radiat Oncol Biol Phys 70:1325–1329

    Article  PubMed  Google Scholar 

  9. Tindall GT, McLanahan CS, Christy JH (1978) Transsphenoidal microsurgery for pituitary tumors associated with hyperprolactinemia. J Neurosurg 48:849–860

    Article  PubMed  CAS  Google Scholar 

  10. Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB (1999) Transsphenoidal microsurgical therapy of prolactinomas: initial outcomes and long-term results. Neurosurgery 44:254–261

    Article  PubMed  CAS  Google Scholar 

  11. Saeki N, Nakamura M, Sunami K, Yamaura A (1998) Surgical indication after bromocriptine therapy on giant prolactinomas: effects and limitations of the medical treatment. Endocr J 45:529–537

    Article  PubMed  CAS  Google Scholar 

  12. Yu C, Wu Z, Gong J (2005) Combined treatment of invasive giant prolactinomas. Pituitary 8:61–65

    Article  PubMed  CAS  Google Scholar 

  13. Ciccarelli E, Camanni F (1996) Diagnosis and drug therapy of prolactinoma. Drugs 51:954–965

    Article  PubMed  CAS  Google Scholar 

  14. Iwai Y, Hakuba A, Khosla VK, Nishikawa M, Katsuyama J, Inoue Y, Nishimura S (1992) Giant basal prolactinoma extending into the nasal cavity. Surg Neurol 37:280–283

    Article  PubMed  CAS  Google Scholar 

  15. Shrivastava RK, Arginteanu MS, King WA, Post KD (2002) Giant prolactinomas: clinical management and long-term follow up. J Neurosurg 97:299–306

    Article  PubMed  Google Scholar 

  16. Wu ZB, Yu CJ, Su ZP, Zhuge QC, Wu JS, Zheng WM (2006) Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: results of a long-term follow up. J Neurosurg 104:54–61

    Article  PubMed  CAS  Google Scholar 

  17. Colao A, Di Sarno A, Sarnacchiaro F, Ferone D, Di Renzo G, Merola B, Annunziato L, Lombardi G (1997) Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 82:876–883

    Article  PubMed  CAS  Google Scholar 

  18. Gillam MP, Molitch ME, Lombardi G, Colao A (2006) Advances in the treatment of prolactinomas. Endocr Rev 27:485–534

    Article  PubMed  CAS  Google Scholar 

  19. Corvol J, Anzouan-Kacou J, Fauveau E, Bonnet A, Lebrun-Vignes B, Girault C, Agid Y, Lechat P, Isnard R, Lacomblez L (2007) Heart valve regurgitation, pergolide use, and Parkinson disease: an observational study and meta-analysis. Arch Neurol 64:1721–1726

    Article  PubMed  Google Scholar 

  20. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G (2007) Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med 356:39–46

    Article  PubMed  CAS  Google Scholar 

  21. Antonini A, Poewe W (2007) Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson’s disease. Lancet Neurol 6:826–829

    Article  PubMed  CAS  Google Scholar 

  22. Kars M, Delgado V, Holman ER, Feelders RA, Smit JW, Romijn JA, Bax J, Pereira AM (2008) Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab 93:3348–3356

    Article  PubMed  CAS  Google Scholar 

  23. Kars M, Pereira AM, Bax JJ, Romijn JA (2008) Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required. Eur J Endocrinol 159:363–367

    Article  PubMed  CAS  Google Scholar 

  24. Colao A, Galderisi M, Di Sarno A, Pardo M, Gaccione M, D’Andrea M, Guerra E, Pivonello R, Lerro G, Lombardi G (2008) Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab 93:3777–3784

    Article  PubMed  CAS  Google Scholar 

  25. Cawood TJ, Bridgman P, Hunter L, Cole D (2009) Low-dose cabergoline causing valvular heart disease in a patient treated for prolactinoma. Inter Med J 39:266–267

    Article  CAS  Google Scholar 

  26. Knosp E, Steiner E, Kitz K, Matula C (1993) Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33:610–617

    Article  PubMed  CAS  Google Scholar 

  27. Di Chiro G, Nelson KB (1962) The volume of the sella turcica. Am J Roentgenol Radium Ther Nucl Med 87:989–1008

    PubMed  CAS  Google Scholar 

  28. Hamilton DK, Vance ML, Boulos PT, Laws ER (2005) Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists. Pituitary 8:53–60

    Article  PubMed  Google Scholar 

  29. Fleseriu M, Lee M, Pineyro M, Skugor M, Reddy SK, Siraj ES, Hamrahian AH (2006) Giant invasive pituitary prolactinoma with falsely low serum prolactin: the significance of ‘hook effect’. J Neurooncol 79:41–43

    Article  PubMed  Google Scholar 

  30. Pakzaban P (2000) Giant prolactinoma and hook effect. Neurology 55:1415–1416

    PubMed  CAS  Google Scholar 

  31. Molitch ME (2003) Dopamine resistance of prolactinomas. Pituitary 6:19–27

    Article  PubMed  CAS  Google Scholar 

  32. Molitch ME (2005) Pharmacologic resistance in prolactinoma patients. Pituitary 8:43–52

    Article  PubMed  CAS  Google Scholar 

  33. Molitch ME (2006) Prolactin-secreting tumors: what’s new? Expert Rev Anticancer Ther 6(Suppl 9):S29–S35. doi:10.1586/14737140.6.9s.S29

    Article  PubMed  Google Scholar 

  34. Kupersmith MJ, Kleinberg D, Warren FA, Budzilovitch G, Cooper P (1989) Growth of prolactinoma despite lowering of serum prolactin by bromocriptine. Neurosurgery 24:417–423

    Article  PubMed  CAS  Google Scholar 

  35. Landolt AM, Osterwalder V (1984) Perivascular fibrosis in prolactinomas: is it increased by bromocriptine? J Clin Endocrinol Metab 58:1179–1183

    Article  PubMed  CAS  Google Scholar 

  36. Hong JW, Lee MK, Kim Sh, Lee EJ (2010) Discrimination of prolactinoma from hyperprolactinemic non-functioning adenoma. Endocrine 37:140–147

    Article  PubMed  CAS  Google Scholar 

  37. Colao A, Di Somma C, Pivonello R, Faggiano A, Lombardi G, Savastano S (2008) Medical therapy for clinically non-functioning pituitary adenomas. Endocr Relat Cancer 15:905–915

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

This study was supported by a grant from the Korea Healthcare Technology R&D Project, Ministry for Health, Welfare & Family Affairs, Republic of Korea (No. A085136).

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Yonsei University College of Medicine, 250 Seongsan-no, Seodaemun-gu, Seoul, 120-752, South Korea

    Moon Sool Yang & Sun Ho Kim

  2. Department of Endocrinology, Internal Medicine, Yonsei University College of Medicine, 250 Seongsanno, Seodaemungu, Seoul, 120-752, South Korea

    Jae Won Hong & Eun Jig Lee

  3. Department of Diagnostic Radiology, Yonsei University College of Medicine, Seoul, South Korea

    Seung Koo Lee

  4. Pituitary Tumor Clinic, Yonsei University College of Medicine, Seoul, South Korea

    Moon Sool Yang, Jae Won Hong, Seung Koo Lee, Eun Jig Lee & Sun Ho Kim

Authors
  1. Moon Sool Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jae Won Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Seung Koo Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eun Jig Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sun Ho Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Eun Jig Lee or Sun Ho Kim.

Additional information

M. S. Yang and J. W. Hong contributed equally to this work and should be considered co-first authors.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yang, M.S., Hong, J.W., Lee, S.K. et al. Clinical management and outcome of 36 invasive prolactinomas treated with dopamine agonist. J Neurooncol 104, 195–204 (2011). https://doi.org/10.1007/s11060-010-0459-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-010-0459-3

Keywords

Search

Navigation